Lymph Nodes News and Research RSS Feed - Lymph Nodes News and Research

LJI study could provide important target for autoimmune disease interventions

LJI study could provide important target for autoimmune disease interventions

Follicular helper T cells (Tfh cells), a rare type of T cells, are indispensable for the maturation of antibody-producing B cells. They promote the proliferation of B cells that produce highly selective antibodies against invading pathogens while weeding out those that generate potentially harmful ones. [More]
UGA researcher works to advance effective treatment for infectious mononucleosis

UGA researcher works to advance effective treatment for infectious mononucleosis

The University of Georgia's Mark Ebell wasn't impressed with research on infectious mononucleosis when he wrote his first published review on it back in the 1990s. He still isn't—a subject he discusses in the April issue of the Journal of the American Medical Association. [More]
Radiation therapy better than chemotherapy for stage IIa testicular cancer patients

Radiation therapy better than chemotherapy for stage IIa testicular cancer patients

A large study of testicular cancer patients has shown that radiation therapy is a better treatment than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells but they are less than 2cms in diameter). [More]
Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
Scientists reveal mechanism involved in regulation of lymphangiogenesis

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease. [More]
Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Radical treatment such as surgery and radiation for localized prostate cancer may cause significant side effects. Active surveillance is increasingly accepted as an option for treating patients with clinically insignificant disease to maintain their quality of life. [More]
Antibodies given within one day of SHIV exposure can clear the virus

Antibodies given within one day of SHIV exposure can clear the virus

Scientists at the Oregon National Primate Research Center today revealed that infant rhesus macaques treated with antibodies within 24 hours of being exposed to SHIV, a chimeric simian virus that bears the HIV envelope protein, were completely cleared of the virus. [More]
Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer. [More]
Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis. [More]
New drug combination treatment makes breast cancer tumours disappear in just 11 days

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial. [More]
Understanding role of ethnicity, age in breast cancer prognosis

Understanding role of ethnicity, age in breast cancer prognosis

Although breast cancer is somewhat more aggressive in South Asian and Black women than in White women, this is largely due to age differences between ethnic groups in the UK, according to new research. [More]
Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute. [More]
Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies. [More]
Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy. [More]
New optogenetic technology could turn on immune cells to attack melanoma tumors

New optogenetic technology could turn on immune cells to attack melanoma tumors

A new optogenetic technology developed at UMass Medical School, called optogenetic immunomodulation, is capable of turning on immune cells to attack melanoma tumors in mice. Using near-infrared light, UMMS researchers have shown they can selectively activate an immune response by controlling the flow of calcium ions into the cell. This breakthrough could lead to less invasive, and more controlled and selective, immunotherapies for cancer treatment. [More]
New staging system proposed to identify most appropriate treatments for HPV-related OPC

New staging system proposed to identify most appropriate treatments for HPV-related OPC

Human papillomavirus (HPV) status is a strong predictor of prognosis for patients with oropharyngeal carcinoma (OPC), but the current staging system does not adequately account for biological and clinical differences between HPV-positive OPC and HPV-negative OPC, commonly caused by alcohol and tobacco use. [More]
Most stage III melanoma patients do not benefit from interferon treatment

Most stage III melanoma patients do not benefit from interferon treatment

Final results for the Sunbelt Melanoma Trial, published online this month in the Journal of Clinical Oncology, show that thanks to current diagnostic techniques, most stage III melanoma patients do not benefit from treatment with interferon. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
Advertisement
Advertisement